Latest News

SYGNIS AG Installs Scalable Production Capability for Lightning-Link Antibody Conjugation Technology

January 16th, 2018

Heidelberg, Germany and Cambridge, UK, 16 January 2018: SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard), the Group which includes Expedeon Holdings, Expedeon, and C.B.S. Scientific Company, today announced it has extended the manufacturing capability for its Lightning-Link® technology, currently marketed under the Expedeon brand, to support scalability and bulk production of antibodies. Lightning-Link is…

View

SYGNIS AG launches TruePrime® apoptotic cell free DNA amplification kit for the liquid biopsy market

December 6th, 2017

Heidelberg, Germany and Cambridge, UK, 06 December 2017 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard), the Group which includes Expedeon Holdings, Expedeon, and C.B.S. Scientific Company, today announced the launch of its TruePrime® apoptotic cell free DNA amplification kit, under the Expedeon brand. The kit enables accurate DNA amplification using cell free DNA…

View

SYGNIS AG signs supply agreement with US Biological for the Lightning-Link® antibody labelling technology

November 28th, 2017

Heidelberg, Germany and Cambridge, UK, 28 November 2017 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard), the Group which includes Expedeon Holdings, Expedeon, and C.B.S. Scientific Company, today announced it has signed a supply agreement with US Biological, Salem, MA, USA, for its Innova Lightning-Link® technology. Heikki Lanckriet, CEO and CSO of SYGNIS AG,…

View

SYGNIS AG partners with Abingdon Health to provide full service custom lateral flow assay design and supply

November 7th, 2017

  Cambridge, UK, 07 November 2017: SYGNIS AG, under the Expedeon (Innova) brand name, a specialist provider of bioconjugation products and services, today announced it has established a partnership with Abingdon Health Ltd (“Abingdon”), which will enable Innova to provide its customers with full lateral flow assay development services as well as establishing Innova as…

View

SYGNIS AG announces the launch of the Universal Lateral Flow Assay Kit and associated patent filing

October 25th, 2017

Enables fast and easy development of customized sandwich lateral flow assays Cambridge, UK, 25 October 2017: SYGNIS AG today announced the launch of its Universal Lateral Flow Assay (LFA) kit, the latest addition to its expanding range of lateral flow assay products and services which are being commercialized under the Expedeon brand name. The novel…

View

Move forms part of integration into SYGNIS Group

October 20th, 2017

Madrid, Spain and Heidelberg, Germany, 18 October 2017 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the completion of the relocation of its subsidiary company, Expedeon, into the Company’s existing facilities in Cambridge, UK. The relocation follows the recent acquisition of Expedeon by SYGNIS AG, and the continued integration of Innova within…

View

SYGNIS AG announces completion of relocation of its Expedeon unit to allow for expansion

October 18th, 2017

Move forms part of integration into SYGNIS Group Madrid, Spain and Heidelberg, Germany, 18 October 2017 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the completion of the relocation of its subsidiary company, Expedeon, into the Company’s existing facilities in Cambridge, UK. The relocation follows the recent acquisition of Expedeon by SYGNIS…

View

October 18th, 2017

18 October 2017 SYGNIS AG announces completion of relocation of its Expedeon unit to allow for expansion   Move forms part of integration into SYGNIS Group Madrid, Spain and Heidelberg, Germany, 18 October 2017 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the completion of the relocation of its subsidiary company, Expedeon,…

View

Bioconjugation specialist Expedeon acquired by SYGNIS AG

June 26th, 2017

Innova CEO and CSO Dr. Nick Gee becomes Chief Technical Officer of SYGNIS Madrid, Spain, Heidelberg, Germany, and Cambridge, UK, 26th June 2017: Expedeon (Innova), a specialist provider of bioconjugation products and services, has announced it has been fully acquired by Sygnis AG, for EUR 8 million in cash and 3.5 million in shares. Innova’s…

View

TTP plc and Expedeon extend partnership to develop rapid point-of-care diagnostics

June 13th, 2017

Innova to continue to provide custom bioconjugation services to support TTP’s Desktop Biology initiative Cambridge, UK, 13 June 2017: TTP plc, Europe’s leading technology and product development company, today announces its ongoing partnership with Expedeon (Innova), a specialist provider of bioconjugation products and services, to enable its rapid point-of-care diagnostics development program. TTP’s Desktop Biology…

View

Expedeon Introduces the FlexLISA Kit

May 9th, 2017

Kit Enables Flexibility in Development and Optimization of ELISA Assays Cambridge, UK, 09 May 2017: Expedeon (Innova), a specialist provider of bioconjugation products and services, today announced it has introduced the FlexLISA® kit, providing a flexible tool for development and optimization of sandwich ELISA assays. The FlexLISA kit allows researchers to covalently conjugate up to…

View

New! Alexa Fluor® 488 added to Lightning-Link® range

May 3rd, 2017

Expedeon adds Alexa Fluor® 488 to Lightning-Link® range of antibody labeling kits Enables easy, fast labeling of primary antibodies or proteins with Alexa Fluor 488 Cambridge, UK, 03 May 2017: Expedeon (Innova), a specialist provider of bioconjugation products and services, today announced it has added Alexa Fluor® 488, one of the most popular fluorescent labels…

View

Your preferred local currency is now